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Professor David Anstee, an outstanding, inspirational, 
and visionary scientist, died on 18 October 2021 at the age of 
75. His death will be a great loss to his family, to his friends 
around the world, and to transfusion science. Most readers of 
this journal will know Dave Anstee for his innovative research 
into blood groups, but his research interests into aspects of 
transfusion sciences went well beyond that. His research 
was always directed towards the benefit of patients, whether 
it involved safer blood transfusion, a better understanding 
of parasitic invasion of red cells, or the biochemical bases of 
diseases associated with blood groups. He was also dedicated 
to the delivery of clinical practice.
Dave Anstee was born and brought up in Bedford, England. 
He went to the University of Bristol, England, where he gained 
a BSc and a PhD in Biochemistry. His career in the transfusion 
field, which spanned over 50 years, began at the Bristol 
Transfusion Centre, where he established an immunochem-
istry research laboratory, initially applying polyacrylamide 
gel electrophoresis to the analysis of sialoglycoproteins (later 
called glycophorins), which express the antigens of the MNS 
and Gerbich blood group systems. Dave Anstee was quick to 
recognize the application of monoclonal antibody technology 
to blood group immunochemistry and set about establishing 
a monoclonal antibody laboratory in Bristol. Many valuable 
antibodies to cell-surface markers were produced and are still 
available to the research community as research tools. His 
research teams also participated in the identification of the 
structures expressing the antigens of the Lutheran, Diego, 
Cromer, and Indian blood group systems. In the era of blood 
group molecular genetics, Dave Anstee’s team cloned the Rh 
genes and the genes for the Lutheran and Duffy systems and 
identified the genes for the Diego, Cromer, Indian, Raph, and 
MAM systems.
In 1987, Dave became Director of the Blood Group 
Reference Laboratory (BGRL), located in Oxford, England, 
which already had an impressive international reputation. 
He moved the laboratory to Bristol, expanded it, added 
“International” to its name (IBGRL), and added molecular 
blood group testing to its repertoire. In addition to molecular 
blood group testing of donors and potential transfusion 
recipients, IBGRL introduced fetal blood group determination 
for pregnant women with antibodies and, later, fetal RHD 
testing for all D– pregnant women, to avoid unnecessary 
antenatal immunoglobulin treatment.
In 1995, Dave Anstee established, and became director of, 
the Bristol Institute for Transfusion Sciences (BITS), a research 
institute within the English blood transfusion service and 
affiliated with the University of Bristol. In addition to research, 
BITS incorporated the IBGRL, provided an MSc course in 
Transfusion and Transplantation Sciences, and, in 1999, 
included the Clinical Biotechnology Laboratory, a new facility 
established by Dave Anstee for culturing antibodies and other 
materials under good manufacturing practice conditions and 
suitable for use in therapeutics and clinical trials.
In the late 1990s, Dave Anstee introduced the culturing 
of red cells from hemopoietic precursors into his research 
program. Initially, this was done to study the development of 
red cell surface markers during erythropoiesis, but the plan 
was always to develop a method for in vitro “manufacture” 
of human red cells suitable for blood transfusion, a move 
towards personalized transfusion. This technology was 
further complemented by clustered regularly interspaced 
short palindromic repeats (CRISPR)-mediated gene editing 
of an immortalized human erythroblast cell line towards 
production of genetically modified cultured red cells. In 
2015, Dave Anstee became head of the National Institute for 
Health Research Blood and Transplant Research Unit for the 
manufacturing and clinical assessment of cultured red cells, 
based at the University of Bristol.
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Dave Anstee’s research achievements led to numerous 
prestigious scientific awards. These awards include the Karl 
Landsteiner Memorial Award (2019) and the Emily Cooley 
Memorial Award (1997) from the AABB, the Presidential 
Award (2008) and Jean Juilliard Prize (1990) from the 
International Society of Blood Transfusion, and the James 
Blundell Award (2003) from the British Blood Transfusion 
Society (BBTS). He was president of the BBTS (1999–2000) 
and was Editor of the Society’s journal, Transfusion Medicine, 
for 10 years. He was an author of two textbooks: Applied 
Blood Group Serology (with Peter Issitt) and Mollison’s Blood 
Transfusion in Clinical Medicine (with Harvey Klein).
This catalog of scientific merit ignores the personal side of 
Dave. As a friend, he was interesting, witty, and a fun person, 
whose interests extended well beyond science. As a colleague 
and research collaborator, he was inspiring, generous, and 
quick to give credit where it was due. As a manager, he had 
very much his own style, which involved calmness, tolerance, 
and patience, plus warmth and friendliness towards his staff, 
yet firmness when that was required. I believe those attributes 
created an atmosphere that permeated the organizations he 
led. Finally, he was very much a family man: a husband to 
Margaret (Maggs) for over 50 years and a kind and caring 
father and grandfather of four children and four grandchildren.
Dave Anstee will be sadly missed by so many.
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